Raman Sankar, MD, PhD, FAAN, FAES

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    UCB
    Topic:
    Epilepsy Therapeutics
    Date added:
    07/15/2024
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Jazz Pharmaceuticals
    Topic:
    Epilepsy Therapeutics
    Date added:
    07/15/2024
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Eisai
    Topic:
    Epilepsy Therapeutics
    Date added:
    07/15/2024
    Date updated:
    07/15/2024
    Relationship end date:
    12/30/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    SK Life Sciences
    Topic:
    Epilepsy Therapeutics
    Date added:
    07/15/2024
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Neurelis
    Topic:
    Epilepsy Therapeutics
    Date added:
    07/15/2024
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Ovid Therapeutics
    Topic:
    Epilepsy Drug Development
    Date added:
    07/15/2024
    Date updated:
    07/15/2024
Return to Oct. 4, 2024 Epilepsy Conference: Contemporary Management Trends in Intractable Epilepsy